These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27673381)

  • 21. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.
    Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing.
    Zundler S; Neurath MF
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S19-28. PubMed ID: 26458165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention.
    Aleksandrova K; Romero-Mosquera B; Hernandez V
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28867793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etiopathogenesis of inflammatory bowel disease: today and tomorrow.
    de Souza HSP
    Curr Opin Gastroenterol; 2017 Jul; 33(4):222-229. PubMed ID: 28402995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-trafficking agents in the treatment of inflammatory bowel disease.
    Zundler S; Wiendl M; Neurath MF
    Curr Opin Gastroenterol; 2019 Nov; 35(6):499-506. PubMed ID: 31567498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome.
    Larmonier CB; Shehab KW; Ghishan FK; Kiela PR
    Biomed Res Int; 2015; 2015():504638. PubMed ID: 26583115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development.
    Kang M; Martin A
    Semin Immunol; 2017 Aug; 32():3-13. PubMed ID: 28465070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered.
    Qiao YQ; Cai CW; Ran ZH
    J Dig Dis; 2016 Dec; 17(12):800-810. PubMed ID: 27743467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug delivery strategies for targeted treatment of inflammatory bowel disease].
    Lautenschläger C; Schmidt C; Lange K; Stallmach A
    Z Gastroenterol; 2015 Mar; 53(3):226-34. PubMed ID: 25723326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human gut-on-a-chip technology: will this revolutionize our understanding of IBD and future treatments?
    Lee J; Choi JH; Kim HJ
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):883-5. PubMed ID: 27291426
    [No Abstract]   [Full Text] [Related]  

  • 32. Expanding the drug discovery space with predicted metabolite-target interactions.
    Nuzzo A; Saha S; Berg E; Jayawickreme C; Tocker J; Brown JR
    Commun Biol; 2021 Mar; 4(1):288. PubMed ID: 33674782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of Pediatric Inflammatory Bowel Disease.
    Peloquin JM; Goel G; Villablanca EJ; Xavier RJ
    Annu Rev Immunol; 2016 May; 34():31-64. PubMed ID: 27168239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mast cells and inflammatory bowel disease.
    Boeckxstaens G
    Curr Opin Pharmacol; 2015 Dec; 25():45-9. PubMed ID: 26629596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information.
    Collij V; Festen EA; Alberts R; Weersma RK
    Inflamm Bowel Dis; 2016 Nov; 22(11):2562-2570. PubMed ID: 27753694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future biologic targets for IBD: potentials and pitfalls.
    Melmed GY; Targan SR
    Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):110-7. PubMed ID: 20134493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucocorticoid-Induced Leucine Zipper as a Druggable Target in Inflammatory Bowel Diseases.
    Ronchetti S; Gentili M; Ricci E; Migliorati G; Riccardi C
    Inflamm Bowel Dis; 2020 Jun; 26(7):1017-1025. PubMed ID: 31961437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets.
    Yadav V; Varum F; Bravo R; Furrer E; Bojic D; Basit AW
    Transl Res; 2016 Oct; 176():38-68. PubMed ID: 27220087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol in inflammatory bowel diseases: a brief overview.
    Esposito G; Filippis DD; Cirillo C; Iuvone T; Capoccia E; Scuderi C; Steardo A; Cuomo R; Steardo L
    Phytother Res; 2013 May; 27(5):633-6. PubMed ID: 22815234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolome and inflammasome in inflammatory bowel disease.
    Nanau RM; Neuman MG
    Transl Res; 2012 Jul; 160(1):1-28. PubMed ID: 22687960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.